eWellness Healthcare (EWLL) 10-Q 23 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 23, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-55203
Entity Registrant Name	eWELLNESS HEALTHCARE CORPORATION
Entity Central Index Key	0001550020
Entity Tax Identification Number	90-1073143
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	1126 S Federal Hwy #464
Entity Address, City or Town	Fort Lauderdale
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33316
City Area Code	(855)
Local Phone Number	470-1700
Title of 12(b) Security	Common shares
Trading Symbol	EWLL
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,707,683,627

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash	$ 2,290	$ 1,109
Prepaid expenses		3,235
Total current assets	2,290	4,344
Property & equipment, net	3,053	3,788
TOTAL ASSETS	5,343	8,132
CURRENT LIABILITIES
Accounts payable and accrued expenses	1,007,393	892,164
Accrued expenses - related party	179,064	292,762
Accrued compensation	200,000	200,000
Convertible debt, net of discount	1,354,882	1,354,882
Derivative liability	1,433,783	3,925,106
Total current liabilities	4,175,122	6,664,914
Total Liabilities	4,175,122	6,664,914
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT
Common stock, authorized 20,000,000,000 shares, $.001 par value, 17,707,683,627 and 16,862,481,961 issued and outstanding, respectively	17,707,684	16,862,482
Shares to be issued		263
Subscription receivable	(94,975)
Additional paid in capital	16,723,540	16,097,866
Accumulated deficit	(38,506,864)	(39,618,090)
Total Stockholders’ Deficit	(4,169,779)	(6,656,782)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	5,343	8,132
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred stock value	697	697
Total Stockholders’ Deficit	697	697
Series C Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred stock value	92
Total Stockholders’ Deficit	92
Series D Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred stock value	20
Total Stockholders’ Deficit	20
Series E Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred stock value	27
Total Stockholders’ Deficit	$ 27

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Common stock, shares authorized	20,000,000,000	20,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	17,707,683,627	16,862,481,961
Common stock, shares outstanding	17,707,683,627	16,862,481,961
Series A Preferred Stock [Member]
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	696,667	696,667
Preferred stock, shares outstanding	696,667	696,667
Series C Preferred Stock [Member]
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	920,000	0
Preferred stock, shares outstanding	920,000	0
Series D Preferred Stock [Member]
Preferred stock, shares authorized	200,000	200,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	200,000	0
Preferred stock, shares outstanding	200,000	0
Series E Preferred Stock [Member]
Preferred stock, shares authorized	2,500,000	2,500,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	265,680	0
Preferred stock, shares outstanding	265,680	0

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
REVENUE		$ 123,780		$ 138,155
OPERATING EXPENSES
Executive compensation	260,000	187,000	260,000	374,000
General and administrative	187,687	88,553	210,854	435,243
Professional fees	766,984	383,163	780,804	850,581
Total Operating Expenses	1,214,671	658,716	1,251,658	1,659,824
Loss from Operations	(1,214,671)	(534,936)	(1,251,658)	(1,521,669)
OTHER INCOME (EXPENSE)
Interest income				1
Gain (loss) on derivative liability	713,915	(2,217,052)	2,491,323	(4,199,959)
Loss on disposal of asset		(3,866)		(3,866)
Interest expense	(64,630)	(205,073)	(128,439)	(764,033)
Net Income (Loss) before Income Taxes	(565,386)	(2,960,927)	1,111,226	(6,489,526)
Income tax expense
Net Income (Loss)	$ (565,386)	$ (2,960,927)	$ 1,111,226	$ (6,489,526)
Basic income (loss) per common share	$ 0	$ 0	$ 0	$ 0
Weighted average basic shares outstanding	16,864,183,627	5,181,476,648	16,863,851,274	2,672,747,473
Diluted income (loss) per common share	$ 0	$ 0	$ 0	$ 0
Weighted average diluted shares outstanding	41,592,390,567	32,909,736,603	41,592,390,567	32,909,736,603

Reconciliation of Stockholders'

Reconciliation of Stockholders' Deficit (Unaudited) - USD ($)	Series A Preferred Stock [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Common Stock [Member]	Subscription Receivable [Member]	Shares to be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 250				$ 12,752		$ 150	$ 23,942,830	$ (30,862,019)	$ (6,906,037)
Balance, shares at Dec. 31, 2019	250,000				12,752,084
Shares issued to officers, directors and consultants	$ 227							679,773		680,000
Shares issued to officers, directors and consultants, shares	226,667
Contributed services								108,000		108,000
Shares issued for debt conversion					$ 7,838,257			(6,681,896)		1,156,361
Shares issued for debt conversion, shares					7,838,256,204
Derivative liability								3,360,260		3,360,260
Shares issued for rounding - 50:1 split, shares					47,876
Shares issued for services					$ 668		(74)	191		785
Shares issued for services, shares					668,332
Net profit (loss)									(6,489,526)	(6,489,526)
Ending balance, value at Jun. 30, 2020	$ 477				$ 7,851,725		76	21,409,110	(37,351,545)	(8,090,157)
Balance, shares at Jun. 30, 2020	476,667				7,851,724,496
Shares issued for rounding - 50:1 split					$ 48			(48)
Beginning balance, value at Mar. 31, 2020	$ 375				$ 1,430,006			26,285,825	(34,390,618)	(6,674,412)
Balance, shares at Mar. 31, 2020	375,000				1,430,005,454
Shares issued to officers, directors and consultants	$ 102							304,898		305,000
Shares issued to officers, directors and consultants, shares	101,667
Contributed services								54,000		54,000
Shares issued for debt conversion					$ 6,421,466			(6,047,649)		373,817
Shares issued for debt conversion, shares					6,421,465,710
Derivative liability								812,237		812,237
Shares issued for services					$ 253		76	(201)		128
Shares issued for services, shares					253,332
Net profit (loss)									(2,960,927)	(2,960,927)
Ending balance, value at Jun. 30, 2020	$ 477				$ 7,851,725		76	21,409,110	(37,351,545)	(8,090,157)
Balance, shares at Jun. 30, 2020	476,667				7,851,724,496
Beginning balance, value at Dec. 31, 2020	$ 697				$ 16,862,482		263	16,097,866	(39,618,090)	(6,656,782)
Balance, shares at Dec. 31, 2020	696,667				16,862,481,961
Shares issued to officers, directors and consultants		$ 92	$ 20					1,119,888		1,120,000
Shares issued to officers, directors and consultants, shares		920,000	200,000
Shares issued for cash				$ 35		(94,975)		349,965		$ 255,025
Shares issued for cash, shares				350,000						843,200,000
Shares issued for preferred share conversions				$ (8)	$ 843,200			(843,192)
Shares issued for preferred share conversions, shares				(84,320)	843,200,000
Shares issued for services					$ 2,002		(263)	(987)		752
Shares issued for services, shares					2,001,666
Net profit (loss)									1,111,226	1,111,226
Ending balance, value at Jun. 30, 2021	$ 697	$ 92	$ 20	$ 27	$ 17,707,684	(94,975)		16,723,540	(38,506,864)	(4,169,779)
Balance, shares at Jun. 30, 2021	696,667	920,000	200,000	265,680	17,707,683,627
Beginning balance, value at Mar. 31, 2021	$ 697				$ 16,864,184		195	16,096,833	(37,941,478)	(4,979,569)
Balance, shares at Mar. 31, 2021	696,667				16,864,183,627
Shares issued to officers, directors and consultants		$ 92	$ 20					1,119,888		1,120,000
Shares issued to officers, directors and consultants, shares		920,000	200,000
Shares issued for cash				$ 35		(94,975)		349,965		255,025
Shares issued for cash, shares				350,000
Shares issued for preferred share conversions				$ (8)	$ 843,200			(843,192)
Shares issued for preferred share conversions, shares				(84,320)	843,200,000
Shares issued for services					$ 300		(195)	46		151
Shares issued for services, shares					300,000
Net profit (loss)									(565,386)	(565,386)
Ending balance, value at Jun. 30, 2021	$ 697	$ 92	$ 20	$ 27	$ 17,707,684	$ (94,975)		$ 16,723,540	$ (38,506,864)	$ (4,169,779)
Balance, shares at Jun. 30, 2021	696,667	920,000	200,000	265,680	17,707,683,627

Reconciliation of Stockholder_2

Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical)	Dec. 16, 2019	Jun. 30, 2020
Statement of Stockholders' Equity [Abstract]
Reverse stock split, description	1:50 reverse split	50:1 split

Consolidated Condensed Statem_2

Consolidated Condensed Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net income (loss)	$ 1,111,226	$ (6,489,526)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	736	3,676
Contributed services		108,000
Shares issued to officers, directors and consultants	1,120,000	344,960
Shares issued for consulting services	750	785
Shares issued for financing costs		93,433
Amortization of debt discount and prepaids		725,250
(Gain) loss on derivative liability	(2,491,323)	4,199,959
Loss on disposal of asset		3,866
Changes in operating assets and liabilities
Prepaid expense	3,235	(9,916)
Accounts receivable		(126,237)
Accounts payable and accrued expenses	115,230	513,643
Accounts payable - related party		196,460
Accrued expenses - related party	(113,698)	31,509
Accrued compensation		122,491
Net cash used in operating activities	(253,844)	(281,647)
Cash flows from investing activities
Purchase of equipment
Net cash used in investing activities
Cash flows from financing activities
Proceeds from issuance of convertible debt		52,800
Original issue discount and debt issuance costs		(7,800)
Proceeds from issuance of preferred series E	255,025
Net cash provided by financing activities	255,025	45,000
Net increase (decrease) in cash	1,181	(236,647)
Cash, beginning of period	1,109	240,722
Cash, end of period	2,290	4,075
Cash paid for:
Taxes
Interest Expense
Non cash items:
Shares issued for debt conversion		$ 1,156,360

The Company

The Company	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1. The Company The Company and Nature of Business eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. The Company has generated minimal revenues to date. eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a 15 % ownership in Bistromatics. This agreement eliminated all past due professional fees of $ 748,832 . The transfer of rights was completed on December 31, 2020. During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company has engaged in negotiations with a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”), for a potential business combination. In connection with such negotiations, the Company’s Board of Directors on March 8, 2021, approved the organization of EWLL Acquisition Corp. under the laws of Nevada as a new wholly owned subsidiary of the Company (“EWLL Acquisition”). The purpose of the formation of EWLL Acquisition was in contemplation of its merger with and into AMHP which would be the surviving entity and become a wholly owned subsidiary of the Company. Pursuant to the Company’s intentions referenced above, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition and AMHP pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company, subject to filing of Articles of Merger with the State of Nevada. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist. On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). eWellness Healthcare Corporation Notes to Consolidated Condensed Financial Statements June 30, 2021 (unaudited)

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2021 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2021. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020. The information regarding common stock shares, options and warrants throughout this document have been adjusted to reflect the 1:50 reverse split Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments. Going Concern For the six months ended June 30, 2021, the Company had no revenue. The Company has an accumulated loss of $ 38,506,864 and a working capital deficit of $ 4,172,832 The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. Fair Value of Financial Instruments As of June 30, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis. Summary of Assets and Liabilities Fair Value on Recurring Basis Total Level 1 Level 2 Level 3 Derivative Liability $ 1,433,783 $ - $ - $ 1,433,783 Total Liabilities measured at fair value $ 1,433,783 $ $ $ 1,433,783 eWellness Healthcare Corporation Notes to Consolidated Condensed Financial Statements June 30, 2021 (unaudited) As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 3,925,106 $ $ $ 3,925,106 Total Liabilities measured at fair value $ 3,925,106 $ - $ - $ 3,925,106 Revenue Recognition The Company recognizes revenue per ASC 606. Revenue is recognized when the services have been completed. Reclassifications Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 3. Related Party Transactions Throughout the six months ended June 30, 2021, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of June 30, 2021 and December 31, 2020 were $ 24,064 and $ 11,655 , respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $ 216,107 and $ 216,107 as of June 30, 2021 and December 31, 2020, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $ 200,000 and $ 200,000 as of June 30, 2021 and December 31, 2020, respectively.

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 4. Convertible Notes Payable During the six months ended June 30, 2021, there were no new convertible notes executed. During the six months ended June 30, 2021, the Company accrued interest payable of $ 128,439 Year Ended December 31, 2020 In March 2020, the Company executed a 12 52,800 January 15, 2021 4,800 3,000 70 10 2,880 During the year ended December 31, 2020, the Company accrued interest of $ 330,871 eWellness Healthcare Corporation Notes to Consolidated Condensed Financial Statements June 30, 2021 (unaudited)

Equity Transactions

Equity Transactions	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Equity Transactions	Note 5. Equity Transactions Preferred Stock The total number of shares of Series A Preferred Stock which the Company shall have authority to issue is 20,000,000 0.001 1,000,000 The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 3,000,000 In April 2021, the Board of Directors issued a Certificate of Designations, Preferences, Rights and Limitations of Series C Convertible Preferred Stock. The Board authorized that the Company shall have the authority to issue 1,000,000 .0001 In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights Limitations of Series D Preferred Stock. The Board authorized that the Company shall have the authority issue 200,000 shares with a par value of $ .0001 per share to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock. In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock. The Board authorized that the Company shall have authority to issue 2,500,000 .0001 1.00 The Series C, Series D and Series E Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation ; and (ii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others) existing subsidiaries of the Corporation. The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time. On May 4, 2021, the Board of Directors issued 350,000 shares of Series E Convertible Preferred Stock for the subscription agreements dated March 1, 2021 at the value of $ 1.00 per share. Since the full payment of $ 350,000 had not been received at the period ended June 30, 2021, there is a subscription receivable for $ 94,975 . On May 12, 2021, the Board of Directors authorized the issuance of 200,000 200,000 On May 20, 2021, the Board of Directors authorized the issuance of 920,000 920,000 eWellness Healthcare Corporation Notes to Consolidated Condensed Financial Statements June 30, 2021 (unaudited) Common Stock On February 12, 2020, FINRA approved a 1:50 reverse split 1:50 reverse split 47,876 On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million ( 1,900,000,000 20,000,000,000 Six Months Ended June 30, 2021 During the six months ended June 30, 2021, the Company issued 2,001,666 shares of common stock for consultant services valued at $ 752 . During the six months ended June 30, 2021, the Company issued 843,200,000 84,320 Six Months Ended June 30, 2020 In January 2020, the Company executed a 12-month advisory services agreement. The Company is to issue 20,000 80,000 126 40,000 8 2,500 During the six months ended June 30, 2020, the Company issued a total of 7,838,256,204 959,835 103,093 93,433 During the six months ended June 30, 2020, the Company issued 588,332 1,597 Stock Options The following is a summary of the status of all Company’s stock options as of June 30, 2021 and changes during the six months ended on that date: Summary of Stock Options Activity Weighted Number Average Remaining Intrinsic Options Price Life (yrs) Value Outstanding on December 31, 2020 27,000 $ 40.00 .14 $ - Granted - - Exercised - - Cancelled (27,000 ) - Outstanding on June 30, 2021 - - - $ - Options exercisable on June 30, 2021 - $ - - $ - eWellness Healthcare Corporation Notes to Consolidated Condensed Financial Statements June 30, 2021 (unaudited) Warrants The following is a summary of the status of the Company’s warrants as of June 30, 2021 and changes during the six months ended on that date: Summary of Warrants Activity Weighted Number of Average Exercise Remaining Intrinsic Warrants Price Life (yrs.) Value Outstanding on December 31, 2020 26,015 $ 12.50 1.2 $ - Granted - - - - Exercised - - - - Cancelled (26,015 ) - - - Outstanding on June 30, 2021 - $ - - $ - Warrants exercisable on June 30, 2021 - $ - - $ -

Commitments, Contingencies

Commitments, Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies	Note 6. Commitments, Contingencies The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

Derivative Valuation

Derivative Valuation	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Valuation	Note 7. Derivative Valuation The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes The debt discount is amortized over the life of the note and recognized as interest expense. For the six months ended June 30, 2021 and 2020, the Company amortized the debt discount of $ 0 594,705 During the six months ended June 30, 2021, the Company had the following activity in the derivative liability account: Schedule of Derivative Liability Notes Derivative liability at December 31, 2020 $ 3,925,106 Change in fair value (2,491,323 ) Derivative liability at June 30, 2021 $ 1,433,783 For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows: Schedule of Assumptions Used Black Scholes Valuation of Derivative Stock price at valuation date $ .0006 Risk free interest rate .05 % Stock volatility factor 101.21 % Years to Maturity .08 Expected dividend yield None

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 8. Subsequent Events From July 1 until the filing of this report, the Company issued 1,280,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2021 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2021. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020. The information regarding common stock shares, options and warrants throughout this document have been adjusted to reflect the 1:50 reverse split
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.
Going Concern	Going Concern For the six months ended June 30, 2021, the Company had no revenue. The Company has an accumulated loss of $ 38,506,864 and a working capital deficit of $ 4,172,832 The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As of June 30, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis. Summary of Assets and Liabilities Fair Value on Recurring Basis Total Level 1 Level 2 Level 3 Derivative Liability $ 1,433,783 $ - $ - $ 1,433,783 Total Liabilities measured at fair value $ 1,433,783 $ $ $ 1,433,783 eWellness Healthcare Corporation Notes to Consolidated Condensed Financial Statements June 30, 2021 (unaudited) As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 3,925,106 $ $ $ 3,925,106 Total Liabilities measured at fair value $ 3,925,106 $ - $ - $ 3,925,106
Revenue Recognition	Revenue Recognition The Company recognizes revenue per ASC 606. Revenue is recognized when the services have been completed.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Assets and Liabilities Fair Value on Recurring Basis	As of June 30, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis. Summary of Assets and Liabilities Fair Value on Recurring Basis Total Level 1 Level 2 Level 3 Derivative Liability $ 1,433,783 $ - $ - $ 1,433,783 Total Liabilities measured at fair value $ 1,433,783 $ $ $ 1,433,783 eWellness Healthcare Corporation Notes to Consolidated Condensed Financial Statements June 30, 2021 (unaudited) As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 3,925,106 $ $ $ 3,925,106 Total Liabilities measured at fair value $ 3,925,106 $ - $ - $ 3,925,106

Equity Transactions (Tables)

Equity Transactions (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Summary of Stock Options Activity	The following is a summary of the status of all Company’s stock options as of June 30, 2021 and changes during the six months ended on that date: Summary of Stock Options Activity Weighted Number Average Remaining Intrinsic Options Price Life (yrs) Value Outstanding on December 31, 2020 27,000 $ 40.00 .14 $ - Granted - - Exercised - - Cancelled (27,000 ) - Outstanding on June 30, 2021 - - - $ - Options exercisable on June 30, 2021 - $ - - $ -
Summary of Warrants Activity	The following is a summary of the status of the Company’s warrants as of June 30, 2021 and changes during the six months ended on that date: Summary of Warrants Activity Weighted Number of Average Exercise Remaining Intrinsic Warrants Price Life (yrs.) Value Outstanding on December 31, 2020 26,015 $ 12.50 1.2 $ - Granted - - - - Exercised - - - - Cancelled (26,015 ) - - - Outstanding on June 30, 2021 - $ - - $ - Warrants exercisable on June 30, 2021 - $ - - $ -

Derivative Valuation (Tables)

Derivative Valuation (Tables)	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liability	During the six months ended June 30, 2021, the Company had the following activity in the derivative liability account: Schedule of Derivative Liability Notes Derivative liability at December 31, 2020 $ 3,925,106 Change in fair value (2,491,323 ) Derivative liability at June 30, 2021 $ 1,433,783
Schedule of Assumptions Used Black Scholes Valuation of Derivative	For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows: Schedule of Assumptions Used Black Scholes Valuation of Derivative Stock price at valuation date $ .0006 Risk free interest rate .05 % Stock volatility factor 101.21 % Years to Maturity .08 Expected dividend yield None

The Company (Details Narrative)

The Company (Details Narrative) - USD ($)	Apr. 19, 2021	Sep. 15, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Professional Fees			$ 766,984	$ 383,163	$ 780,804	$ 850,581
Bistromatics Inc. [Member] | Services Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity Method Investment, Ownership Percentage		15.00%
Professional Fees		$ 748,832
American Health Protection Corp [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock conversion basis	(i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”).

Summary of Assets and Liabiliti

Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability	$ 1,433,783	$ 3,925,106
Total Liabilities measured at fair value	1,433,783	3,925,106
Fair Value, Inputs, Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability
Total Liabilities measured at fair value
Fair Value, Inputs, Level 2 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability
Total Liabilities measured at fair value
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability	1,433,783	3,925,106
Total Liabilities measured at fair value	$ 1,433,783	$ 3,925,106

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Dec. 16, 2019	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Reverse stock split, description	1:50 reverse split	50:1 split
Accumulated loss			$ 38,506,864	$ 39,618,090
Working capital deficit			$ 4,172,832

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Accrued Professional Fees	$ 216,107	$ 216,107
Employee-related Liabilities, Current	200,000	200,000
Officers and Directors [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Due to Related Parties, Current	$ 24,064	$ 11,655

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	1 Months Ended
	Mar. 31, 2020USD ($)Trading	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Accrued interest		$ 128,439
12% Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Accrued interest			$ 2,880
Debt interest stated rate	12.00%
Debt face amount	$ 52,800
Debt maturity date	Jan. 15, 2021
Original issue discount	$ 4,800
Transaction costs	$ 3,000
Convertible debt percentage	70.00%
Number of trading days | Trading	10
2019 Convertible Notes [Member]
Short-term Debt [Line Items]
Accrued interest			$ 330,871

Summary of Stock Options Activi

Summary of Stock Options Activity (Details)	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Equity [Abstract]
Number of Stock Options Outstanding, Beginning Balance | shares	27,000
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 40
Remaining Life (yrs) Outstanding, Beginning Balance	1 month 20 days
Intrinsic Value Outstanding, Beginning Balance | $
Number of Stock Options Outstanding, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Number of Stock Options Outstanding, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Stock Options Outstanding, Cancelled | shares	(27,000)
Weighted Average Exercise Price, Cancelled | $ / shares
Number of Stock Options Outstanding, Ending Balance | shares
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares
Remaining Life (yrs) Outstanding, Ending Balance
Intrinsic Value Outstanding, Ending Balance | $
Number of Stock Options exercisable, Ending Balance | shares
Weighted Average Exercise Price Options exercisable, Ending Balance | $ / shares
Remaining Life (yrs) Options exercisable, Ending Balance
Intrinsic Value Outstanding, Beginning Balance | $
Intrinsic Value Options exercisable, Ending Balance | $

Summary of Warrants Activity (D

Summary of Warrants Activity (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Equity [Abstract]
Number of Warrants, Outstanding, Beginning Balance | shares	26,015
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance	$ 12.50
Remaining Life (yrs.) Warrants Outstanding, Beginning Balance	1 year 2 months 12 days
Intrinsic Value, Warrants Outstanding, Beginning Balance
Number of Warrants, Granted | shares
Weighted Average Exercise Price, Warrants Granted
Remaining Life (yrs.) Warrants Outstanding, Granted
Intrinsic Value, Warrants Outstanding, Granted
Number of Warrants, Exercised | shares
Weighted Average Exercise Price, Warrants Exercised
Remaining Life (yrs.) Warrants Outstanding, Exercised
Intrinsic Value, Warrants Outstanding, Exercised
Number of Warrants, Cancelled | shares	(26,015)
Weighted Average Exercise Price, Warrants Cancelled
Remaining Life (yrs.) Warrants Outstanding, Cancelled
Intrinsic Value, Warrants Outstanding, Cancelled
Number of Warrants, Outstanding, Ending Balance | shares
Weighted Average Exercise Price, Warrants Outstanding, Ending Balance
Remaining Life (yrs.) Warrants Outstanding, Ending Balance
Intrinsic Value, Warrants Outstanding, Ending Balance
Number of Warrants, exercisable, Ending balance | shares
Weighted Average Exercise Price Exercisable, Ending Balance
Remaining Life (yrs.) Warrants Exercisable, Ending Balance
Intrinsic Value, Warrants Outstanding, Exercisable

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	May 04, 2021	Feb. 12, 2020	Dec. 16, 2019	Jan. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2019	May 20, 2021	May 12, 2021	Apr. 30, 2021	Dec. 31, 2020	Apr. 30, 2020	Feb. 14, 2020
Class of Stock [Line Items]
Deferred compensation					$ 3,000,000		$ 3,000,000
Preferred Stock, Voting Rights							The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time.
Number of shares issued, new issues							843,200,000
Stock issued during the period, value					255,025		$ 255,025
Subscription receivable					$ 94,975		$ 94,975
Reverse stock split, description			1:50 reverse split					50:1 split
Common stock, shares authorized					20,000,000,000		20,000,000,000						20,000,000,000
Value for services					$ 151	$ 128	$ 752	$ 785
Convertible Notes [Member]
Class of Stock [Line Items]
Shares issued for debt conversion, shares								7,838,256,204
Principal amount						959,835		$ 959,835
Accrued interest						103,093		103,093
Financing costs								93,433
12- month Advisory Services Agreement [Member]
Class of Stock [Line Items]
Number of shares issued, new issues				80,000			40,000
Stock issued during the period, value				$ 126			$ 8
Monthly base fee						$ 2,500		$ 2,500
12- month Advisory Services Agreement [Member] | Monthly [Member]
Class of Stock [Line Items]
Number of shares issued, new issues				20,000
Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock, description							The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance.
Conversion of Stock, Shares Converted							40
Common Stock [Member]
Class of Stock [Line Items]
Stock issued during the period, value
Common stock, shares authorized					20,000,000,000		20,000,000,000								1,900,000,000
Shares issued for services					300,000	253,332	2,001,666	668,332
Value for services					$ 300	$ 253	$ 2,002	$ 668
Shares issued for debt conversion, shares						6,421,465,710		7,838,256,204
Officers,Directors and Consultants [Member]
Class of Stock [Line Items]
Preferred stock shares authorized									1,000,000
Board of Directors [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued, new issues									47,876
Reverse stock split, description		1:50 reverse split							1:50 reverse split
Consultant [Member]
Class of Stock [Line Items]
Shares issued for services							2,001,666	588,332
Value for services							$ 752	$ 1,597
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized					20,000,000		20,000,000						20,000,000
Preferred stock par value					$ 0.001		$ 0.001						$ 0.001
Stock issued during the period, value
Preferred stock value					697		697						$ 697
Value for services
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized					1,000,000		1,000,000						1,000,000
Preferred stock par value					$ 0.0001		$ 0.0001						$ 0.0001
Stock issued during the period, value
Preferred stock value					92		92
Value for services
Series C Preferred Stock [Member] | Board of Directors [Member]
Class of Stock [Line Items]
Preferred stock shares authorized												1,000,000
Preferred stock par value												$ 0.0001
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized					200,000		200,000						200,000
Preferred stock par value					$ 0.0001		$ 0.0001						$ 0.0001
Stock issued during the period, value
Preferred stock value					20		20
Value for services
Series D Preferred Stock [Member] | Board of Directors [Member]
Class of Stock [Line Items]
Preferred stock shares authorized														200,000
Preferred stock par value												0.0001
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized					2,500,000		2,500,000						2,500,000
Preferred stock par value					$ 0.0001		$ 0.0001						$ 0.0001
Number of shares issued, new issues					350,000		350,000
Stock issued during the period, value					$ 35		$ 35
Preferred stock value					27		27
Value for services
Series E Preferred Stock [Member] | Board of Directors [Member]
Class of Stock [Line Items]
Preferred stock shares authorized														2,500,000
Preferred stock par value												0.0001
Offering price per share												$ 1
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Offering price per share	$ 1
Number of shares issued, new issues	350,000
Stock issued during the period, value	$ 350,000
Shares issued for debt conversion, shares							84,320
Series D Voting Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized											200,000
Preferred stock value											$ 200,000
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized										920,000
Preferred stock value										$ 920,000

Schedule of Derivative Liabilit

Schedule of Derivative Liability (Details) - Notes [Member]	6 Months Ended
	Jun. 30, 2021USD ($)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability, beginning balance	$ 3,925,106
Change in fair value	(2,491,323)
Derivative liability, ending balance	$ 1,433,783

Schedule of Assumptions Used Bl

Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) - Derivative Liability [Member]	6 Months Ended
	Jun. 30, 2021$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price at valuation date	$ 0.0006
Derivative liability, term	29 days
Measurement Input, Risk Free Interest Rate [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Derivative liability, fair value measurement input, percentage	0.05
Measurement Input, Price Volatility [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Derivative liability, fair value measurement input, percentage	101.21
Measurement Input, Expected Dividend Rate [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Derivative liability, fair value measurement input, percentage	0

Derivative Valuation (Details N

Derivative Valuation (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amortized of debt discount		$ 725,250
Derivative Liability [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amortized of debt discount	$ 0	$ 594,705

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	2 Months Ended
	Aug. 20, 2021shares
Subsequent Event [Member] | Series E Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Shares issued during period for services, shares	1,280,000